Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease

• Published in: International journal of molecular sciences Vol. 20; no. 13; p. 3265
• Main Authors: Cannone, Valentina, Cabassi, Aderville, Volpi, Riccardo, Burnett, John C.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 02.07.2019; MDPI
• Subjects: Animals; Atrial Natriuretic Factor - genetics; Atrial Natriuretic Factor - metabolism; Atrial Natriuretic Factor - pharmacology; Atrial Natriuretic Factor - therapeutic use; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - genetics; Cardiovascular Diseases - metabolism; Genetic Variation; Humans; Insulin resistance; Kinases; Metabolic Diseases - drug therapy; Metabolic Diseases - genetics; Metabolic Diseases - metabolism; Molecular Targeted Therapy; Obesity; Plasma; Review; Studies; United States > US; metabolic syndrome; heart failure; natriuretic peptides; cardiometabolic disease; cGMP; atrial natriuretic peptide; hypertension; obesity; guanylyl cyclase receptor A
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms20133265

Atrial natriuretic peptide (ANP) is a cardiac hormone with pleiotropic cardiovascular and metabolic properties including vasodilation, natriuresis and suppression of the renin-angiotensin-aldosterone system. Moreover, ANP induces lipolysis, lipid oxidation, adipocyte browning and ameliorates insulin sensitivity. Studies on ANP genetic variants revealed that subjects with higher ANP plasma levels have lower cardio-metabolic risk. In vivo and in humans, augmenting the ANP pathway has been shown to exert cardiovascular therapeutic actions while ameliorating the metabolic profile. MANP is a novel designer ANP-based peptide with greater and more sustained biological actions than ANP in animal models. Recent studies also demonstrated that MANP lowers blood pressure and inhibits aldosterone in hypertensive subjects whereas cardiometabolic properties of MANP are currently tested in an on-going clinical study in hypertension and metabolic syndrome. Evidence from in vitro, in vivo and in human studies support the concept that ANP and related pathway represent an optimal target for a comprehensive approach to cardiometabolic disease.